Balance Sheet Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-11 pm EDT			5-day change	1st Jan Change
35.84 ^USD	-0.78%		-1.46%	+40.49%

Jun. 30	Royalty Pharma plc(NasdaqGS:RPRX) dropped from Russell 1000 Value-Defensive Index	CI
Jun. 30	Royalty Pharma plc(NasdaqGS:RPRX) dropped from Russell 1000 Defensive Index	CI

2c8b6f3ea8b.ihvVp4s9rLWhQlcFcWuLkmAeCJstqhmLuXXEp_3diPY.53a43vF4883AEWRSMx7D2g5_ZOtG4FLUjTmcyJiw-c_hX-zd7lvPxNh6Yw

Published financial data: ROYALTY PHARMA PLC

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	2.12B	2.29B	2.24B	2.35B	2.26B
Total Revenues	2.12B	2.29B	2.24B	2.35B	2.26B
Cost of Goods Sold, Total	231M	453M	904M	561M	732M
Gross Profit	1.89B	1.84B	1.33B	1.79B	1.53B
Selling General & Admin Expenses, Total	182M	183M	227M	250M	237M
R&D Expenses	26.29M	200M	177M	52M	2M
Amortization of Goodwill and Intangible Assets - (IS)	23.06M	23M	5.67M	-	-
Other Operating Expenses, Total	231M	406M	410M	302M	239M
Operating Income	1.66B	1.43B	923M	1.49B	1.29B
Interest Expense, Total	-168M	-166M	-188M	-187M	-226M
Interest And Investment Income	28.38M	53.54M	78.34M	72.29M	47.34M
Net Interest Expenses	-140M	-113M	-110M	-115M	-178M
Income (Loss) On Equity Invest.	44.46M	-19.49M	-8.97M	28.88M	29.61M
Other Non Operating Income (Expenses)	-14.9M	-27.21M	81.86M	-24.03M	-7.53M
EBT, Excl. Unusual Items	1.55B	1.27B	886M	1.38B	1.14B
Gain (Loss) On Sale Of Investments	247M	-30.21M	-40.26M	318M	194M
Gain (Loss) On Sale Of Assets	-	-	-	-	-
Asset Writedown	-65.05M	-	-616M	-	-
Other Unusual Items	-30.5M	-	-	-	-
EBT, Incl. Unusual Items	1.7B	1.24B	230M	1.7B	1.33B
Earnings From Continuing Operations	1.7B	1.24B	230M	1.7B	1.33B
Net Income to Company	1.7B	1.24B	230M	1.7B	1.33B
Minority Interest	-727M	-621M	-187M	-565M	-472M
Net Income - (IS)	975M	620M	42.83M	1.13B	859M
Preferred Dividend and Other Adjustments	480M	-	-	-	-
Net Income to Common Incl Extra Items	495M	620M	42.83M	1.13B	859M
Net Income to Common Excl. Extra Items	495M	620M	42.83M	1.13B	859M
Per Share Items
Net EPS - Basic	1.32	1.49	0.1	2.54	1.92
Basic EPS - Continuing Operations	1.32	1.49	0.1	2.54	1.92
Basic Weighted Average Shares Outstanding	375M	415M	438M	448M	448M
Net EPS - Diluted	1.32	1.49	0.1	2.53	1.91
Diluted EPS - Continuing Operations	1.32	1.49	0.1	2.53	1.91
Diluted Weighted Average Shares Outstanding	375M	415M	438M	603M	594M
Normalized Basic EPS	0.64	0.42	0.84	0.67	0.53
Normalized Diluted EPS	0.64	0.42	0.84	0.5	0.4
Dividend Per Share	0.3	0.68	0.76	0.8	0.84
Payout Ratio	40.8	46.02	778.21	31.58	43.83
Supplemental Items
EBITDA	1.68B	1.45B	929M	1.5B	-
EBITA	1.68B	1.45B	929M	1.49B	1.29B
EBIT	1.66B	1.43B	923M	1.49B	1.29B
Total Revenues (As Reported)	2.12B	2.29B	2.24B	2.35B	2.26B
Normalized Net Income	242M	173M	367M	299M	238M
Interest on Long-Term Debt	157M	166M	-	-	-
Supplemental Operating Expense Items
General and Administrative Expenses	182M	183M	227M	250M	237M
Research And Development Expense From Footnotes	26.29M	200M	177M	52M	2M
Stock-Based Comp., G&A Exp. (Total)	5.7M	3.1M	2.17M	2.36M	2.34M
Total Stock-Based Compensation	5.7M	3.1M	2.17M	2.36M	2.34M

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	1.01B	1.54B	1.71B	477M	929M
Short Term Investments	1.05B	648M	25.72M	18.3M	58.2M
Trading Asset Securities, Total	-	-	-	-	-
Total Cash And Short Term Investments	2.06B	2.19B	1.74B	495M	987M
Accounts Receivable, Total	626M	683M	728M	775M	811M
Other Receivables	-	-	-	-	-
Total Receivables	626M	683M	728M	775M	811M
Other Current Assets, Total	8.6M	6.63M	90.52M	3.8M	4.19M
Total Current Assets	2.7B	2.88B	2.55B	1.27B	1.8B
Long-term Investments	898M	910M	736M	1.01B	1.26B
Other Intangibles, Total	28.67M	5.67M	14.5M	1.78M	5.32M
Accounts Receivable Long-Term	12.37B	13.72B	13.49B	14.09B	15.13B
Other Long-Term Assets, Total	28.6M	4.14M	15.13M	4.74M	28.21M
Total Assets	16.02B	17.52B	16.81B	16.38B	18.22B
Liabilities
Accounts Payable, Total	10.78M	5.62M	7.91M	15.16M	13.37M
Accrued Expenses, Total	60.75M	57.7M	54.16M	51.68M	98.06M
Current Portion of Long-Term Debt	-	-	998M	-	998M
Other Current Liabilities	236M	108M	107M	94.53M	144M
Total Current Liabilities	308M	171M	1.17B	161M	1.25B
Long-Term Debt	5.82B	7.1B	6.12B	6.14B	6.61B
Other Non Current Liabilities	-	-	2.5M	900K	12.08M
Total Liabilities	6.12B	7.27B	7.29B	6.3B	7.88B
Common Stock, Total	102K	106K	107K	108K	108K
Additional Paid In Capital	2.87B	3.51B	3.67B	4.01B	4.1B
Retained Earnings	1.92B	2.26B	1.96B	2.52B	2.85B
Treasury Stock	-2.32M	-2.72M	-2.81M	-2.63M	-2.66M
Comprehensive Income and Other	34.4M	16.49M	-	-	-
Total Common Equity	4.82B	5.78B	5.63B	6.53B	6.95B
Minority Interest	5.08B	4.47B	3.9B	3.56B	3.4B
Total Equity	9.9B	10.25B	9.53B	10.08B	10.34B
Total Liabilities And Equity	16.02B	17.52B	16.81B	16.38B	18.22B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	388M	433M	443M	447M	433M
ECS Total Common Shares Outstanding	388M	433M	443M	447M	446M
Book Value / Share	12.42	13.34	12.7	14.61	15.58
Tangible Book Value	4.79B	5.77B	5.61B	6.52B	6.94B
Tangible Book Value Per Share	12.34	13.33	12.67	14.61	15.56
Total Debt	5.82B	7.1B	7.12B	6.14B	7.61B
Net Debt	3.75B	4.91B	5.38B	5.64B	6.63B
Minority Interest, Total (Incl. Fin. Div)	5.08B	4.47B	3.9B	3.56B	3.4B
Equity Method Investments, Total	455M	435M	397M	376M	379M
Account Code - Inventory Valuation	3	3	3	3	3

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	975M	620M	42.83M	1.13B	859M
Amortization of Goodwill and Intangible Assets - (CF)	23.06M	23M	5.67M	-	-
Depreciation & Amortization, Total	23.06M	23M	5.67M	-	-
Amortization of Deferred Charges, Total - (CF)	11.72M	20.16M	21.36M	20.5M	19.56M
(Gain) Loss From Sale Of Asset	-	-	-	-	-
(Gain) Loss on Sale of Investments - (CF)	-247M	30.21M	40.26M	-318M	-194M
Asset Writedown & Restructuring Costs	65.05M	-	616M	-	-
(Income) Loss On Equity Investments - (CF)	-2.12M	53.87M	48.12M	-10.06M	-16.22M
Stock-Based Compensation (CF)	5.43M	2.44M	2.17M	2.36M	2.34M
Provision and Write-off of Bad Debts	231M	-1.61B	904M	561M	732M
Other Operating Activities, Total	735M	581M	-2.08B	-1.61B	-1.67B
Change In Accounts Receivable	162M	2.3B	2.54B	3.2B	2.98B
Change In Accounts Payable	-766K	-4.59M	2.29M	6.24M	-2.29M
Change in Other Net Operating Assets	76.36M	8.4M	-6.08M	-3.44M	55.67M
Cash from Operations	2.03B	2.02B	2.14B	2.99B	2.77B
Sale of Property, Plant, and Equipment	-	-	-	-	-
Sale (Purchase) of Intangible assets	-2.18B	-2.19B	-1.74B	-2.12B	-2.51B
Investment in Marketable and Equity Securities, Total	-577M	340M	712M	57.17M	-99.45M
Other Investing Activities, Total	-	-18.6M	-	-14.44M	-72.96M
Cash from Investing	-2.76B	-1.87B	-1.03B	-2.07B	-2.68B
Short Term Debt Issued, Total	-	-	-	350M	-
Long-Term Debt Issued, Total	11.89B	1.27B	-	-	1.47B
Total Debt Issued	11.89B	1.27B	-	350M	1.47B
Short Term Debt Repaid, Total	-	-	-	-350M	-
Long-Term Debt Repaid, Total	-11.21B	-	-	-1B	-
Total Debt Repaid	-11.21B	-	-	-1.35B	-
Issuance of Common Stock	1.15B	-	-	-	-
Repurchase of Common Stock	-	-	-	-305M	-230M
Common Dividends Paid	-398M	-285M	-333M	-358M	-376M
Common & Preferred Stock Dividends Paid	-398M	-285M	-333M	-358M	-376M
Other Financing Activities, Total	53.99M	-602M	-612M	-486M	-504M
Cash from Financing	1.49B	385M	-945M	-2.15B	361M
Net Change in Cash	762M	532M	170M	-1.23B	452M
Supplemental Items
Cash Interest Paid	103M	130M	170M	169M	160M
Levered Free Cash Flow	-1.09B	-1.55B	-1.38B	-1.25B	-1.76B
Unlevered Free Cash Flow	-994M	-1.46B	-1.29B	-1.15B	-1.64B
Change In Net Working Capital	-122M	191M	131M	-31.66M	-58.44M
Net Debt Issued / Repaid	681M	1.27B	-	-1B	1.47B

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	7.29	5.33	3.36	5.62	4.67
Return on Total Capital	7.38	5.41	3.39	5.68	4.73
Return On Equity %	21.22	12.32	2.33	17.34	13.03
Return on Common Equity	9.07	11.7	0.75	18.67	12.75
Margin Analysis
Gross Profit Margin %	89.12	80.22	59.58	76.19	67.64
SG&A Margin	8.56	7.99	10.16	10.61	10.46
EBITDA Margin %	79.32	63.5	41.51	63.61	-
EBITA Margin %	79.32	63.5	41.51	63.37	57.1
EBIT Margin %	78.24	62.49	41.25	63.37	57.1
Income From Continuing Operations Margin %	80.19	54.21	10.28	72.2	58.79
Net Income Margin %	45.94	27.07	1.91	48.2	37.95
Net Avail. For Common Margin %	23.33	27.07	1.91	48.2	37.95
Normalized Net Income Margin	11.41	7.56	16.39	12.68	10.53
Levered Free Cash Flow Margin	-51.21	-67.52	-61.87	-52.89	-77.69
Unlevered Free Cash Flow Margin	-46.81	-63.87	-57.58	-48.8	-72.33
Asset Turnover
Asset Turnover	0.15	0.14	0.13	0.14	0.13
Receivables Turnover (Average Receivables)	3.8	3.5	3.17	3.13	2.88
Short Term Liquidity
Current Ratio	8.76	16.81	2.19	7.9	1.44
Quick Ratio	8.73	16.77	2.11	7.87	1.43
Operating Cash Flow to Current Liabilities	6.61	11.78	1.84	18.51	2.21
Days Sales Outstanding (Average Receivables)	96.37	104.35	115.07	116.5	127.05
Average Days Payable Outstanding	17.4	6.61	2.73	7.51	7.13
Long Term Solvency
Total Debt/Equity	58.78	69.24	74.71	60.84	73.6
Total Debt / Total Capital	37.02	40.91	42.76	37.83	42.4
LT Debt/Equity	58.78	69.24	64.24	60.84	63.96
Long-Term Debt / Total Capital	37.02	40.91	36.77	37.83	36.84
Total Liabilities / Total Assets	38.23	41.49	43.35	38.44	43.24
EBIT / Interest Expense	9.89	8.61	4.91	7.97	5.73
EBITDA / Interest Expense	10.02	8.75	4.94	8	-
(EBITDA - Capex) / Interest Expense	10.02	8.75	4.94	8	-
Total Debt / EBITDA	3.46	4.88	7.66	4.1	-
Net Debt / EBITDA	2.23	3.38	5.79	3.77	-
Total Debt / (EBITDA - Capex)	3.46	4.88	7.66	4.1	-
Net Debt / (EBITDA - Capex)	2.23	3.38	5.79	3.77	-
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	16.98	7.87	-2.28	5.24	-3.86
Gross Profit, 1 Yr. Growth %	-33.25	-2.9	-27.42	34.58	-14.65
EBITDA, 1 Yr. Growth %	-36.4	-13.65	-36.12	61.31	-
EBITA, 1 Yr. Growth %	-36.4	-13.65	-36.12	60.69	-13.38
EBIT, 1 Yr. Growth %	-36.7	-13.84	-35.49	61.68	-13.38
Earnings From Cont. Operations, 1 Yr. Growth %	-30.85	-27.07	-81.46	638.96	-21.72
Net Income, 1 Yr. Growth %	-58.48	-36.44	-93.09	2.55K	-24.31
Normalized Net Income, 1 Yr. Growth %	-81.77	-24.87	111.72	-18.56	-20.15
Diluted EPS Before Extra, 1 Yr. Growth %	-	12.97	-93.44	2.49K	-24.54
Accounts Receivable, 1 Yr. Growth %	27.48	8.99	6.63	6.48	6.56
Total Assets, 1 Yr. Growth %	28.68	9.34	-4.01	-2.57	11.24
Tangible Book Value, 1 Yr. Growth %	-20.87	20.48	-2.73	16.23	6.38
Common Equity, 1 Yr. Growth %	-21.08	19.88	-2.57	15.96	6.44
Cash From Operations, 1 Yr. Growth %	22.04	-0.84	6.27	39.36	-7.32
Levered Free Cash Flow, 1 Yr. Growth %	218.6	42.24	-10.49	-10.03	41.2
Unlevered Free Cash Flow, 1 Yr. Growth %	606.31	47.16	-11.94	-10.81	42.5
Dividend Per Share, 1 Yr. Growth %	-	126.67	11.76	5.26	5
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	8.74	12.34	2.67	1.41	0.59
Gross Profit, 2 Yr. CAGR %	1.05	-19.49	-16.05	-1.17	7.18
EBITDA, 2 Yr. CAGR %	9.75	-25.89	-25.73	1.51	-
EBITA, 2 Yr. CAGR %	9.75	-25.89	-25.73	1.31	17.98
EBIT, 2 Yr. CAGR %	10.32	-26.15	-25.45	2.12	18.34
Earnings From Cont. Operations, 2 Yr. CAGR %	5.89	-28.99	-63.23	17.03	140.51
Net Income, 2 Yr. CAGR %	-15.87	-48.63	-79.04	35.32	347.82
Normalized Net Income, 2 Yr. CAGR %	-33.96	-63.89	26.12	31.31	-19.36
Diluted EPS Before Extra, 2 Yr. CAGR %	-81.25	-	-72.77	30.4	342.15
Accounts Receivable, 2 Yr. CAGR %	10.77	17.87	7.8	6.55	5.54
Total Assets, 2 Yr. CAGR %	18.7	18.61	2.45	-3.29	4.11
Tangible Book Value, 2 Yr. CAGR %	4.19	-2.36	8.26	6.33	11.2
Common Equity, 2 Yr. CAGR %	3.62	-2.73	8.07	6.29	11.1
Cash From Operations, 2 Yr. CAGR %	12.13	10	2.65	21.69	13.64
Levered Free Cash Flow, 2 Yr. CAGR %	-	112.88	12.84	-10.26	12.71
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	222.4	13.85	-11.38	12.74
Dividend Per Share, 2 Yr. CAGR %	-	-	59.16	8.47	5.13
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	9.92	8.45	7.24	3.52	-0.38
Gross Profit, 3 Yr. CAGR %	16.47	-0.28	-22.23	-1.75	-5.88
EBITDA, 3 Yr. CAGR %	20.05	1.32	-29.47	-3.82	-
EBITA, 3 Yr. CAGR %	20.05	1.32	-29.47	-3.94	-3.84
EBIT, 3 Yr. CAGR %	20.9	1.59	-29.4	-3.5	-3.33
Earnings From Cont. Operations, 3 Yr. CAGR %	8.21	-6.49	-54.62	-0.04	2.35
Net Income, 3 Yr. CAGR %	-6.94	-23.38	-73.68	5.19	11.5
Normalized Net Income, 3 Yr. CAGR %	-16.49	-32.18	-34.89	9.01	11.25
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-65.89	-	24.31	8.67
Accounts Receivable, 3 Yr. CAGR %	-	10.18	14	7.36	5.9
Total Assets, 3 Yr. CAGR %	-	15.49	10.53	0.75	1.33
Tangible Book Value, 3 Yr. CAGR %	-	9.36	-2.48	10.85	6.35
Common Equity, 3 Yr. CAGR %	-	8.78	-2.68	10.64	6.34
Cash From Operations, 3 Yr. CAGR %	12.78	7.63	8.74	13.66	11.13
Levered Free Cash Flow, 3 Yr. CAGR %	-	-	59.5	4.64	4.38
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	-	109.21	4.95	3.82
Dividend Per Share, 3 Yr. CAGR %	-	-	-	38.67	7.3
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-	-	6.96	5.58	4.52
Gross Profit, 5 Yr. CAGR %	-	-	2.17	-0.64	-11.58
EBITDA, 5 Yr. CAGR %	-	-	-0.93	1.39	-
EBITA, 5 Yr. CAGR %	-	-	-0.93	1.32	-13.36
EBIT, 5 Yr. CAGR %	-	-	-0.36	1.81	-13.2
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	-29.73	2.29	-11.57
Net Income, 5 Yr. CAGR %	-	-	-48.74	-3.8	-18.22
Normalized Net Income, 5 Yr. CAGR %	-	-	-2.49	-11.66	-29.07
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-	-41.67	-
Accounts Receivable, 5 Yr. CAGR %	-	-	-	8.71	10.54
Total Assets, 5 Yr. CAGR %	-	-	-	7.58	7.92
Tangible Book Value, 5 Yr. CAGR %	-	-	-	8.14	2.77
Common Equity, 5 Yr. CAGR %	-	-	-	7.78	2.61
Cash From Operations, 5 Yr. CAGR %	-	-	8.62	13.05	10.68
Levered Free Cash Flow, 5 Yr. CAGR %	-	-	-	-	38.82
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	-	-	-	63.37